DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» CD137
CD137
4-1BB Signaling Beyond T Cells
Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
Tools for Cell Therapy and Immunoregulation
Megakaryopoiesis in Dengue Virus Infected K562 Cell Promotes Viral Replication Which Inhibits 2 Endomitosis and Accumulation of ROS Associated with Differentiation
Flow Reagents Single Color Antibodies CD Chart
How Relevant Are Bone Marrow-Derived Mast Cells (Bmmcs) As Models for Tissue Mast Cells? a Comparative Transcriptome Analysis of Bmmcs and Peritoneal Mast Cells
Role of ADAM10 and ADAM17 in Regulating CD137 Function
Molecular Biology of Hodgkin Lymphoma
CD137 Expression in Tumor Vessel Walls High Correlation with Malignant Tumors
Human CD Marker Chart Reviewed by HLDA1 Bdbiosciences.Com/Cdmarkers
Augmentation of CD134 (OX40)-Dependent NK Anti-Tumour
CD137 Plays Both Pathogenic and Protective Roles in Type 1 Diabetes Development in NOD Mice
Compass Therapeutics Jefferies 2019 Global Healthcare Conference June 7Th, 2019
CD137+ T-Cells: Protagonists of the Immunotherapy Revolution
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-Cell Immunity Directed Against Mutated Calreticulin in Myeloproliferative Neoplasms
CD System of Surface Molecules
Systematic Analysis of CD39, CD103, CD137 and PD-1 As Biomarkers for Naturally
First-In-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Þ Follicular and Other CD20 Non-Hodgkin Lymphomas a C Ajay K
Top View
B-Cell Maturation Antigen (BCMA) As a Target for New Drug Development in Relapsed And/Or Refractory Multiple Myeloma
Supplementary Information
CD137 As a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert
Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor
Chain Ζ CD137 in Series with Signals from the TCR CD28, Inducible
Of Human B Cells CD137 Promotes Proliferation and Survival
First-In-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination
The CD137 Ligand Is Important for Type 1 Diabetes Development But
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity That Is Dependent on Target Coengagement
Characterization of the Human T Cell Response to in Vitro CD27
Expression of Immune Checkpoint Receptors on Peripheral Blood Immune Cells Using a 10-Color Assay on the BD Facslyric™ Flow Cytometer
Serum Concentrations of Soluble 4-1BB and 4-1BB Ligand Correlated with the Disease Severity in Rheumatoid Arthritis
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy Atsushi Yonezawa1,2, Suparna Dutt3, Cariad Chester1,4, Jeewon Kim5, and Holbrook E
Isolation of T Cell Receptors Targeting Recurrent Neoantigens in Hematological Malignancies Vanessa M
Anticancer Immunity Induced by a Synthetic Tumor-Targeted CD137 Agonist
Chimeric Antigen Receptor T Cell Targeting B Cell Maturation Antigen Immunotherapy Is Promising for Multiple Myeloma
CD137 As an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development